Study of Lixelle for amyloid disease in dialysis
Part of Bones, joints & muscles, Kidney & urinary clinical trials.
This study looks at whether Lixelle helps treat dialysis-related amyloidosis in people who receive hemodialysis three times a week. It may help reduce symptoms caused by amyloid deposits that can build up in tissues over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You receive hemodialysis (HD) three times per week
- Your dialysis-related amyloidosis diagnosis is confirmed by specific tests (like a tissue biopsy) or a specific pattern of symptoms/images
- You do not have rheumatoid arthritis, osteoporosis, or osteoarthritis as your diagnosis
- You are not planning a kidney transplant during the study
- You can safely take blood thinners (anticoagulation), and no heart/bleeding/pump-related problem prevents treatment
- You agree to avoid pregnancy during the study and can complete questionnaires with help if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a diabetes medicine called dapagliflozin can help protect kidney function in people with AL amyloidosis. You must live in Michigan and have stable or improving protein in your urine.
This study tests a new drug that targets two proteins on the cells causing amyloidosis, aiming to reduce the harmful protein buildup in the body. It is for people who have just been diagnosed with this condition and have not yet had other treatments for it.
This trial tests a new drug called HLX79 (a human sialidase fusion protein) combined with rituximab, compared to a placebo, for people with active membranous nephropathy (a kidney disease). It aims to see if this combination can reduce protein in the urine and improve kidney function.
This study tests whether the drug LXB (sodium oxybate) can help clear abnormal protein buildup in the brain's small blood vessels (CAA). Participants will take LXB nightly for 8 weeks and have MRIs and spinal taps to measure changes.
This trial tests a three-drug combination (selinexor, daratumumab, and dexamethasone) for people with a specific type of amyloidosis that affects the heart. The goal is to see if this treatment can help reduce the abnormal proteins causing the disease and improve symptoms.
This trial is testing a device called Lucie to help manage hydration in people on dialysis. It looks at how well the device works by measuring body water levels.
Hear when a new Dialysis Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.